A Phase 2 interventional study of BMS-986368 and Placebo in Multiple Sclerosis Spasticity, sponsored by Celgene. Recruiting at 61 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Muscle Spasticity with a site in United States — 34 open to participants now, 44 under way, none of them phase 3. Muscle Spasticity · United States.
Among the 165 studies in Muscle Spasticity with a site in United States, this one is the 19th largest by planned enrollment of the 130 interventional ones that give a count, is one of 4 that started in 2025, is one of 18 in phase 2, reaches primary completion later than 19 of the 43 other live ones, and was the 148th registered.
622 studies on the registry are indexed under Muscle Spasticity; 128 are open to participants now.
Browse Muscle Spasticity studies →34 of the 165 studies in Muscle Spasticity with a site in United States are open now. Recruiting first, the newest first:
Kessler Foundation · Sites in United States
Ages 22+
Kessler Foundation · Sites in United States
Ages 18+
Alberto Esquenazi · Sites in United States
Ages 18–80
Martin Piazza · Sites in United States
Ages 3–14
Yale University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 29 · Phase 3 25 · Phase 4 9
First in 1997; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 36 across 473 interventional studies indexed under Muscle Spasticity.
Median enrollment 31 across the 130 interventional studies, 55 across the 34 observational. Of the 108 that completed or were terminated, 44 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 165 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
Bristol-Myers Squibb has 1 study filed under Muscle Spasticity — fewer than ten, so there is no comparison to draw.
17 of the studies in Muscle Spasticity with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07516067Martin PiazzaSpinal Cord Stimulation for Children With Cerebral Palsy | 2026-11 |
| NCT07792616University of Mississippi Medical CenterElectrical Neuromodulation for Modifying Spinal Network Involved in Spasticity | 2026-12-31 |
| NCT05094362Medical University of South CarolinaOperant Conditioning of Spinal Reflexes Training System--Reflex Operant Down Conditioning | 2026-12-31 |
| NCT06070233Ohio State UniversityRadiosurgery Treatment for Spasticity Associated With Stroke, SCI & Cerebral Palsy | 2026-12-31 |
| NCT06341023University of Illinois at ChicagoFunctional Balance Intervention in Multiple Sclerosis | 2027-01-09 |
Add all 17 to your calendar (.ics) → With an account.
Among the 165 studies in Muscle Spasticity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986368
Drug: BMS-986368
Drug: BMS-986368
Drug: Placebo
Specified dose on specified days
Specified dose on specified days
Change from baseline in Total Numeric-transformed Modified Ashworth Scale-Most Affected Lower Limb (TNmAS-MALL) score
Time frame: At week 6
Change from baseline on the Numeric Rating Scale Spasticity (NRS-S) score
Time frame: At week 6
Change from baseline on the MS Spasticity Scale (MSSS-88) total scores
Time frame: At week 6
Change from baseline on the Timed 25-Foot Walk (T25FW) score
Time frame: At week 6
Change from baseline on the Clinical Global Impression of Severity (CGI-S) score
Time frame: At week 6
Plasma concentrations of BMS-986368 at selected pre- and post-dose time points
Time frame: Up to week 6
Number of participants with Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to week 16
Serious adverse events (SAEs)
Time frame: Up to week 16
Adverse events (AEs) leading to treatment discontinuation
Time frame: Up to week 16
AEs leading to death
Time frame: Up to week 16
AEs leading to clinically significant lab abnormalities
Time frame: Up to week 16
Number of participants with suicidal ideation and behavior during BMS-986368 administration as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to week 16
Number of participants with withdrawal symptoms following BMS-986368 administration as assessed by the Cannabis Withdrawal Scale (CWS)
Time frame: Up to week 15
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Jun 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Irafamdastat